Sarepta Therapeutics Inc (SRPT) Director Hans Lennart Rudolf Wigzell Sells 6,667 Shares
Sarepta Therapeutics Inc (NASDAQ:SRPT) Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Sarepta Therapeutics Inc (NASDAQ SRPT) traded down $0.96 during trading on Monday, reaching $54.29. 1,227,552 shares of the company’s stock were exchanged, compared to its average volume of 2,292,642. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics Inc has a 52 week low of $26.26 and a 52 week high of $57.57.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The company had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. During the same quarter in the prior year, the firm earned ($0.95) EPS. equities research analysts forecast that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.
Several analysts recently commented on the stock. Credit Suisse Group reiterated an “outperform” rating and issued a $81.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Robert W. Baird reiterated a “buy” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, October 17th. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $55.00 price target (up previously from $50.00) on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have given a buy rating to the company’s stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus price target of $64.14.
WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/04/sarepta-therapeutics-inc-srpt-director-hans-lennart-rudolf-wigzell-sells-6667-shares.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.